Back to Search
Start Over
Doxorubicin and cyclophosphamide followed by weekly docetaxel as neoadjuvant treatment of early breast cancer: analysis of biological markers in a GEICAM phase II study
- Source :
- Clinicaltranslational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico. 11(1)
- Publication Year :
- 2009
-
Abstract
- To evaluate the sequential administration of doxorubicin (A) and cyclophosphamide (C) followed by weekly docetaxel in women with stage II to IIIA breast cancer.Patients received 60 mg/m(2) of A and 600 mg/m(2) of C every three weeks for four cycles followed by 12 infusions of weekly docetaxel at a dose of 36 mg/m(2) and with a 2-week resting period.Sixty-three women were included. On an intention-to- treat basis, clinical response rate was 90% (95% CI: 83-98), with 46% complete responses. Breast-conserving surgery could be performed in 43 patients (68%). Complete pathological responses in the breast were confirmed in 17% of patients. No correlations between levels of expression of topoisomerase II alpha, survivin or p27 and the pathological response were detected. The study treatment was generally well tolerated.Neoadjuvant AC followed by weekly docetaxel is a feasible regimen for patients with early-stage breast cancer.
- Subjects :
- Oncology
Adult
Cancer Research
medicine.medical_specialty
Cyclophosphamide
Anthracycline
Survivin
Phases of clinical research
Breast Neoplasms
Docetaxel
Inhibitor of Apoptosis Proteins
Breast cancer
Antigens, Neoplasm
Internal medicine
Proliferating Cell Nuclear Antigen
Antineoplastic Combined Chemotherapy Protocols
medicine
Biomarkers, Tumor
Humans
Doxorubicin
skin and connective tissue diseases
neoplasms
Aged
Neoplasm Staging
Aged, 80 and over
Taxane
business.industry
General Medicine
Middle Aged
medicine.disease
Immunohistochemistry
Neoadjuvant Therapy
DNA-Binding Proteins
DNA Topoisomerases, Type II
Female
Taxoids
Breast carcinoma
business
therapeutics
Microtubule-Associated Proteins
medicine.drug
Subjects
Details
- ISSN :
- 1699048X
- Volume :
- 11
- Issue :
- 1
- Database :
- OpenAIRE
- Journal :
- Clinicaltranslational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico
- Accession number :
- edsair.doi.dedup.....23e4ce4523219b9b7dc8c3f9f073245f